Monopar Therapeutics Inc (MNPR) AI Stock Analysis

• Market Cap: $465.11M
• Dividend Yield: N/A
• Average Volume (3M): 264.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.37
• Revenue Growth: N/A
• EPS Growth: -73.48%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.48
• Shares Outstanding: 6,682,584
• 10 Day Avg. Volume: 327,504
• 30 Day Avg. Volume: 264,856
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.02
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -21.87
• 1Y Price Target: $112.91
• Price Target Upside: 68.42% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $67.00 ▼(-0.06% Downside)

The score is driven primarily by mixed financial performance—strong, low-debt balance sheet but ongoing pre-revenue losses and increasing cash burn. Technicals add downside pressure due to a clear downtrend, while the recent positive Phase 2 update provides an offsetting catalyst; valuation support is limited because earnings are negative and no dividend yield is provided.

Positive Factors

Strong Cash Position

A strong cash position and no debt provide Monopar with financial flexibility, crucial for sustaining operations and funding R&D without immediate revenue.

Strategic Leadership

The new CFO brings extensive industry experience, likely enhancing financial strategy and operations, which is vital for navigating the biotech sector's challenges.

Board Expertise

With over 20 years in investor relations, Talukdar's expertise is expected to strengthen Monopar's strategic direction and governance, aiding long-term growth.

Negative Factors

Negative Cash Flows

Consistent negative cash flows highlight reliance on external funding, posing risks to financial health if product development does not lead to commercialization.

No Revenue Generation

Lack of revenue generation is a significant risk for sustainability, as ongoing R&D expenses require successful product commercialization to improve financial stability.

Increased Financial Strain

The increased net loss indicates heightened financial strain, emphasizing the need for strategic management and successful drug development to achieve profitability.

Monopar Therapeutics Inc Business Overview & Revenue Model

Company Description

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

How the Company Makes Money

Monopar Therapeutics Inc. primarily makes money through the development and potential commercialization of its drug candidates. The company is in a clinical-stage, meaning its revenue model is largely oriented towards the successful advancement of its drug pipeline through clinical trials. Revenue streams may include potential milestone payments and royalties from partnerships or licensing agreements with larger pharmaceutical companies. Additionally, Monopar may receive government grants or funding from non-profit organizations to support its research and development efforts. The company's financial success is heavily reliant on the clinical and regulatory success of its product candidates, as well as its ability to establish strategic collaborations.

Monopar Therapeutics Inc Financial Statement Overview

Summary

Monopar Therapeutics faces typical early-stage biotech challenges with no revenue and ongoing losses. Despite a strong cash position and no debt, the reliance on external financing and negative cash flows pose risks. The focus on transitioning from R&D to commercialization is crucial for long-term financial sustainability.

Income Statement

Monopar Therapeutics Inc has shown consistent negative EBIT and net income figures over the years, reflecting ongoing operational challenges. The company has not generated any revenue, which is expected in early-stage biotech firms but poses significant risks for sustainability without revenue growth. The lack of gross profit margin and net profit margin metrics further underscores the absence of sales revenue. The substantial increase in net loss in 2024 signals heightened financial strain.

Balance Sheet

The balance sheet reveals a strong cash position with no debt, which is a positive indicator of financial flexibility. The equity ratio remains healthy, suggesting that the company is well-capitalized. However, the company's assets and equity have become more volatile, as evidenced by the large equity increase in 2024, potentially from financing activities. The absence of revenue generation remains a challenge for long-term viability.

Cash Flow

Operating cash flows have been negative consistently, indicating cash outflows from core operations. The significant increase in financing cash flows in 2024 suggests reliance on external funding for cash needs. Free cash flow remains negative, which is typical for biotech firms in development stages but highlights the need for successful product development and commercialization to improve cash flow health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-20.04M	-16.16M	-8.83M	-10.54M	-9.13M	0.00
Net Income	-19.44M	-15.59M	-8.40M	-10.52M	-9.10M	-6.30M
Balance Sheet
Total Assets	144.20M	60.29M	7.35M	13.23M	20.52M	16.87M
Cash, Cash Equivalents and Short-Term Investments	143.68M	60.21M	7.27M	13.12M	20.30M	16.74M
Total Debt	102.24K	0.00	0.00	8.41K	0.00	0.00
Total Liabilities	2.64M	5.25M	1.76M	3.14M	1.58M	1.18M
Stockholders Equity	141.56M	55.04M	5.59M	10.09M	18.94M	15.69M
Cash Flow
Free Cash Flow	-10.83M	-6.40M	-7.86M	-7.23M	-7.32M	-4.66M
Operating Cash Flow	-10.83M	-6.40M	-7.86M	-7.23M	-7.32M	-4.66M
Investing Cash Flow	-15.60M	-14.34M	4.93M	-4.92M	0.00	0.00
Financing Cash Flow	148.10M	59.29M	2.03M	32.87K	10.88M	8.18M

Monopar Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 67.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MNPR, the sentiment is Positive. The current price of 67.04 is above the 20-day moving average (MA) of 66.63, below the 50-day MA of 75.60, and above the 200-day MA of 54.80, indicating a neutral trend. The MACD of -2.80 indicates Negative momentum. The RSI at 50.65 is Neutral, neither overbought nor oversold. The STOCH value of 79.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MNPR.

Monopar Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VNDA	60 Neutral	$455.04M	-5.38	-16.72%	―	11.12%	-406.76%
MNPR	53 Neutral	$465.11M	-20.24	-26.54%	―	―	-73.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CRDF	48 Neutral	$189.28M	-3.54	-102.71%	―	-27.29%	16.40%
VSTM	48 Neutral	$511.42M	-1.59	-2888.70%	―	33.79%	-26.37%
SLN	47 Neutral	$277.26M	-3.51	―	―	―	―
MREO	44 Neutral	$90.26M	―	-69.98%	―	―	―

Monopar Therapeutics Inc Corporate Events

Monopar Therapeutics Unveils Promising Phase 2 Study Results

On November 9, 2025, Monopar Therapeutics presented new data from the Phase 2 ALXN1840-WD-204 copper balance study at The Liver Meeting® 2025. The study showed that ALXN1840 (tiomolybdate choline) led to rapid and sustained improvement in daily copper balance in Wilson disease patients, primarily through increased fecal copper excretion, marking a significant advancement in treatment options for this condition.

The most recent analyst rating on (MNPR) stock is a Buy with a $115.00 price target. To see the full list of analyst forecasts on Monopar Therapeutics Inc stock, see the MNPR Stock Forecast page.